CIK 0001672688 · Services-Commercial Physical & Biological Research (SIC 8731) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 4.5 M | 5.7 M | 4.8 M | |
| Net income (USD) | -115.2 M | -110.6 M | -104.9 M | |
| Diluted EPS (USD/shares) | -0.84 | -1.2 | -1.15 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-14 | 4 | FORM 4 | 2026-10-12 |
| 2026-10-14 | 4 | FORM 4 | 2026-10-12 |
| 2026-10-14 | 4 | FORM 4 | 2026-10-12 |
| 2026-09-01 | 4 | FORM 4 | 2026-08-31 |
| 2026-08-11 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-11 | 8-K | 8-K items 2.02,8.01,9.01 | 2026-08-11 |
| 2026-08-07 | 4 | FORM 4 | 2026-03-03 |
| 2026-08-07 | 3 | FORM 3 | 2026-03-03 |
| 2026-07-06 | 4 | FORM 4 | 2026-06-30 |
| 2026-06-26 | 4 | FORM 4 | 2026-06-24 |
| 2026-06-24 | 8-K | 8-K items 1.01,8.01,9.01 | 2026-06-24 |
| 2026-06-24 | 424B5 | 424B5 | |
| 2026-06-24 | 8-K | 8-K items 8.01 | 2026-06-24 |
| 2026-06-15 | 4/A | FORM 4/A | 2026-06-04 |
| 2026-06-11 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-05 | 8-K | 8-K items 5.07 | 2026-06-04 |
| 2026-06-01 | 4 | FORM 4 | 2026-05-31 |
| 2026-05-13 | 4 | FORM 4 | 2026-05-13 |
| 2026-05-07 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-07 | 8-K | 8-K items 2.02,8.01,9.01 | 2026-05-07 |
Forms on file (last 1,000): 4 131, 8-K 56, 3 23, 10-Q 16, SCHEDULE 13G/A 12, CORRESP 10, UPLOAD 9, 4/A 8. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ABSI (0.002 USD), /gw/filings/filings?ticker=ABSI&form=8-K, /gw/filings/facts?ticker=ABSI&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange